Why the lack of promotion may matter, and where this thesis could still fail
Nine articles. One thesis.
Nine articles. One thesis, but not a closed case.
A company with best-in-class clinical data. An accelerating commercial launch. A deliberately constructed board that includes a medtech operator who has already built and sold a company to Boston Scientific. A second manufacturing line being built in North Carolina. A COO departure handled with unusually formal language. An analyst asking publicly about Boston Scientific integration. And a silence from the parties most capable of changing the narrative.
⚠️ Reader notice: The author holds a position or has active interest in NSPR at the time of writing. Nothing in this article constitutes financial advice. All analysis is based on publicly available information. Do your own due diligence.
To me, those pieces do not prove an outcome. They do, however, describe a company that may be more strategically important than its current price suggests.
The market sees $1.65.
I see a thesis that still has to earn confirmation, through adoption, execution, broader indications, and, possibly, strategic interest.
If those confirmations fail to arrive, the market may be right.
If they do arrive, today’s price may eventually look less like skepticism and more like delay.
The Complete Series
- Article 1: InspireMD (NSPR): The Stent Nobody Is Watching, the product, the technology, and the market opportunity.
- Article 2: What The Job Postings Told Me About InspireMD (NSPR), the publicly available hiring data that suggests a story the stock price may not yet reflect.
- Article 3: ‘InspireMD (NSPR) Competition: Why The Problem Isn’t Fully Solved Yet’, What the other players in carotid stenting actually offer, and why that matters for InspireMD’s position.
- Article 4: Why Boston Scientific (BSX) Could Be The Logical Buyer Of InspireMD (NSPR), the strategic logic behind one plausible medtech outcome, and why the fit is worth taking seriously.
- Article 5: InspireMD (NSPR) Catalysts: Timeline For 2026, the specific events that will determine whether this thesis plays out this year or next.
- Article 6: The Architects: the people building InspireMD (NSPR) and why this team looks built for the next phase.
- Article 7: The Syndicate Supporting the Thesis of InspireMD, 48 institutions, one thesis.
- Article 8: Why InspireMD (NSPR) Stock May Be Getting So Little Promotion, a more careful look at silence as a possible signal.
- Article 9: InspireMD (NSPR): Reading The Silence, the final piece, and the limits of the thesis.
🟢 Disclosure: The author holds a position or has active interest in this name.
⚠️ I produce these analyses for my own enjoyment and because I’m always looking for new opportunities. I am not a financial professional, and I don’t have access to professional-grade tools or proprietary data. Everything here is built from publicly available information and my own reasoning — which means I can be wrong. I may not always see the full picture, and my views will change as new information emerges or as I come to understand data points I initially overlooked or underweighted. I only operate with cash positions — no leverage, no margin, no shorting. I never bet against the market or individual companies. My analysis reflects the company’s fundamentals, not its price action. The company is not its price, and the price is not the company. I express my own opinions. I am not receiving compensation to share this. I have no business relationship with any company whose stock is mentioned in this